文献速递肾移植

BAASIS自报的免疫抑制药物不依从可预测肾移植受者的移植物排斥反应

Self-reported non-adherence to immunosuppressive medication detected by the BAASIS predicts allograft rejections in kidney transplant recipients.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

这项前瞻性队列研究纳入维也纳医科大学2018至2019年移植的226例连续肾移植受者,移植后2年内用BAASIS评估依从性,主要终点为活检证实的移植物排斥。55%受者至少一次自报不依从,不依从者排斥发生率24% vs 依从者7%(P<.001),校正后HR为2.90(95%CI 1.51-5.58;P=.001)。作者认为BAASIS具有临床价值,纳入常规移植后管理可能有助于识别不依从并及时干预。

要点

  • 226例肾移植受者中125例(55%)至少一次自报不依从。
  • 不依从者排斥24%(n=30)vs 依从者7%(n=7),P<.001。
  • 校正后不依从与排斥相关,HR 2.90(95%CI 1.51-5.58;P=.001)。

核心结论

  • 研究结果支持BAASIS的临床价值,将其纳入常规移植后管理可能有助于识别临床相关的不依从并及时干预。

研究设计与样本

  • 前瞻性队列研究,纳入2018至2019年在维也纳医科大学移植的226例连续肾移植受者,移植后2年内监测免疫抑制药物依从性。
  • BAASIS在首次门诊随访及移植后第3、6、9、12和24个月应用,评估依从性的执行期和持续期。
  • 不依从定义为对任一BAASIS条目作出任何阳性回答;主要终点为最长随访4年内经活检证实、按Banff会议报告定义的移植物排斥。

主要发现

  • 总研究队列中位年龄56岁(IQR 46-63),女性75例(33%)。
  • 125例受者(55%)至少一次自报不依从;自报不依从在移植后前3个月内从11%升至31%,在移植后第6至24个月维持在27%至32%之间。
  • 中位随访3.7年(IQR 1.0-4.0)期间,不依从受者的移植物排斥多于依从患者(24%,n=30 vs. 7%,n=7;P<.001)。
  • 采用时间依赖Cox回归模型,校正受者性别、移植时年龄和既往移植史后,既往报告的不依从与移植物排斥相关的校正风险比为2.90(95%CI 1.51-5.58;P=.001)。

临床怎么用

  • 作者认为BAASIS具有临床价值,将其纳入常规移植后管理可能有助于识别临床相关的不依从并及时干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After kidney transplantation adherence to immunosuppressive medication is crucial for graft survival and its assessment requires valid measurements. The Basel Assessment of Adherence-to Immunosuppressive Medications Scale (BAASIS) is a validated self-report tool to detect non-adherence, however, its ability to predict clinically relevant outcomes remains to be established. METHODS: In this prospective cohort study including 226 consecutive kidney graft recipients transplanted at the Medical University of Vienna between 2018 and 2019 the adherence toward immunosuppressive medication was monitored for 2 years after transplantation. The BAASIS was applied at the first outpatient visit and at months 3, 6, 9, 12, and 24 post-transplant to assess the implementation and persistence phase of adherence. Non-adherence was defined by any positive response to one of the BAASIS-items. The primary endpoint was biopsy-proven allograft rejection defined by the Banff meeting report during a maximum follow-up of 4 years. RESULTS: Of the total study cohort [median age 56 years (IQR 46-63), 75 (33%) female], 125 recipients (55%) reported non-adherence at least once. Self-reported non-adherence increased within the first 3 months from 11% to 31% and remained between 27% and 32% at months 6 to 24 post-transplant. Non-adherent recipients experienced more allograft rejections than adherent patients (24%, n = 30 vs. 7%, n = 7; P < .001) during a median follow-up of 3.7 years (IQR 1.0-4.0). Using a time-dependent Cox regression model, the adjusted hazard ratio for allograft rejection associated with previously reported non-adherence was 2.90 (95% confidence interval (CI) 1.51-5.58; P = .001) accounting for recipient sex, age at transplantation, and history of previous transplantation. CONCLUSION: Our findings support the clinical value of the BAASIS. Its implementation into routine post-transplant care may facilitate the identification of clinically relevant medication non-adherence, enabling timely interventions.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Haupenthal F, Doberer K, Kapps S, et al. Self-reported non-adherence to immunosuppressive medication detected by the BAASIS predicts allograft rejections in kidney transplant recipients. Nephrol Dial Transplant. 2025. PMID: 40295140. doi:10.1093/ndt/gfaf078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。